TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05243719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADP101
Description: Active dry powder formulation at various volumes.
Study: NCT05455814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shambhavi Madamudra Kriya
Description: The intervention is taught at the Inner Engineering program offered by non-profit Isha Foundation as online as well as in-person formats. It incorporates a combination of different breathing patterns and meditative components. The intervention training provides precise, step by step and easy to follow instructions on how to perform this practice. Performed in a seated posture, this is a simple, safe and accessible intervention that requires no previous experience of meditation. The intervention selected for this study was shown to significantly reduce perceived stress, enhance self-reported general well-being, improve positive emotions, mindfulness, sleep, engagement, relationships, and may promote enhanced Heart Rate Variability and Sympathovagal balance.
Study: NCT05645718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by (IV) vein
Study: NCT05483660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Description: 1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans
Description: 1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum + Bacillus coagulans
Description: 1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
Study: NCT04706091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 10-mg or 20-mg suvorexant capsules
Study: NCT05483660

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adult milk powder 15 g pertime, three times daily and half an hour before meal.
Study: NCT04594018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finlândia Association + finasteride placebo
Description: Finlândia association hair lotion + finasteride placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil + finasteride
Description: Minoxidil hair lotion + Finasteride 1 mg
Study: NCT05141357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000 in combination with pembrolizumab
Description: Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.
Study: NCT06089655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGMS
Description: The Intervention group is to use CGMS to estimate the effect on blood glucose (HbA1C).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGMS
Description: The Intervention group is to use CGMS to estimate the effect on blood glucose (HbA1C).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI diet application
Description: The Intervention group is to use an AI diet application to estimate the effect on blood glucose (HbA1C).
Study: NCT04706091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 10-mg or 20-mg suvorexant capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules
Study: NCT06278155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social relation training with social robot
Description: The protocol is divided in two sections: basic and advanced social relations.~The basic social relationssection consists of 4 stages:~Stage 1 focuses on spontaneous eye contact between the child and the robot Strage 2 introduces the goal of spontaneously looking at a peer Stage 3 focuses on respecting the turn between children Stage 4 aims to encourage peer cooperation Nao social robot helps children to develop specific social skills.~The advanced social relation section consists of 5 stages:~Stage 1: The goal is to initiate physical interaction with a peer during a game Stage 2 is focused on mand (verbal requests) directed to peers Stage 3: The goal is to respond spontaneously to questions or statements from peers In the Stage 4 the child should to play with peers for at least 5 minutes Stage 5: the goal is to conduct at least 4 verbal exchanges on a given topic with peers At each stage, Nao provides verbal prompts to guide the child toward the appropriate response

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional social relations training
Description: Traditional social relations training is the same as the experimental one, however in this context the entire protocol is conducted without the aid of social robot NAO.
Study: NCT05241938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSLT
Description: PSLT will be performed under topical anesthesia (proxymetacaine hydrochloride 5mg/ml eye drops) using a mirrored gonioscopy lens (Latina Ocular Instruments). A α2 agonist hypotensive eye drops (0.2% brimonidine tartrate) and 2% pilocarpine eye drops are applied 40 minutes before the procedure. After laser treatment, the patient will be instructed to use non-steroidal anti-inflammatory eye drops (thrice daily for 7 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin analogue eye drops
Description: Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
Study: NCT03454997

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training including in-person and online
Description: training, motivational interviewing practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training including in-person and online
Description: training, motivational interviewing practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: organizational strategy meetings
Description: meetings with leadership to optimize implementation of evidence-based practices

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: organizational strategy meetings
Description: meetings with leadership to optimize implementation of evidence-based practices

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: performance coaching
Description: to enhance ability to deliver the weight management intervention
Study: NCT04746157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse intervention
Description: Patients will undergo an individualized patient care plan conducted by a lead nurse. According to their results on the Stroke Riskometer and their cardiovascular risk factors, the nurse will prepare a phone call for the next two weeks with information and support adapted to each patient and their necessities. Phone calls will be repeated monthly until the sixth month, then, one more the ninth month and one last previous to the end of the treatment. Patients will be able to contact the reference nurse whenever they would need to.
Study: NCT05645718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given by (IV) vein
Study: NCT06115057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: Subjects in this study are to consume the study product twice daily during regular meals.~The fiber mix consists of different types of dietary fiber that are individually well tolerated for human consumption.
Study: NCT05678088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oropharyngeal Exercises
Description: The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal Exercises
Description: The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Exercises
Description: The participant will practice exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength.
Study: NCT06014957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: 12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), immediately positioned supine with one pillow supporting the head and shoulders
Study: NCT05433324

Intervention type: OTHER
Intervention: MRI and PET Scans
Description: All groups will undergo cognitive tests and brain imaging scans (MRI \& PET)
Study: NCT06014957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saddle block
Description: 12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), placed in the sitting position for ten minutes and then supine with one pillow supporting the head and shoulders
Study: NCT05525312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open-lung protective ventilation strategy
Description: In the open-lung group, the positive end-tidal pressure (PEEP) is titrated to match the best lung compliance. During a PEEP decrement trial, PEEP is decreased from 20 cmH2O to 4 cmH2O by steps of 2 cmH2O/minute, and the driving the transpulmonary pressure (PTP) is calculated at each level of PEEP. In the open-lung group, the targeted PEEP corresponds to the lowest driving PTP during the PEEP decrement trial, meaning the best lung compliance. Thereafter, the PEEP is set at this level and maintained until extubation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard protective ventilation strategy
Description: In the standard group, the positive end-tidal pressure (PEEP) is arbitrarily set at 5 cmH2O, since this is the currently recommended level of PEEP, commonly used in control groups of previous clinical trials.
Study: NCT05645718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given by (IV) vein
Study: NCT05433324

Intervention type: OTHER
Intervention: MRI and PET Scans
Description: All groups will undergo cognitive tests and brain imaging scans (MRI \& PET)

Intervention type: OTHER
Intervention: MRI and PET Scans
Description: All groups will undergo cognitive tests and brain imaging scans (MRI \& PET)
Study: NCT06111820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Access to Community Therapies (iACT)
Description: The Low-intensity Acceptance and Commitment Therapy (LIACT) protocol is based on the empirically supported Acceptance and Commitment Therapy (ACT), and is designed by registered clinical psychologists with consultation from local ACT experts from the Association of Contextual and Behavioural Science (Hong Kong Chapter). The LIACT protocol is also piloted and revised by clinical psychologists to ensure its adaptability to local situations. For individual guided self-help LIACT service, an intake assessment will be conducted to assess the presenting problem of the participants at pre-treatment to ensure the suitability to receive LIACT service. Participants will be given the LIACT self-help workbook collaboratively with a Psychological Wellbeing Practitioner (PWP). Between each session, clients will read through the workbook and complete the exercises suggested in the workbook. In subsequent sessions, PWP will guide clients to overcome the difficulties in performing the LIACT exercises.
Study: NCT05369377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 80mg po qd 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
Study: NCT05508542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises
Description: Personal information form, Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be applied to the pregnant women at the first interview. Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. Afterwards, the Relaxation Exercises CD will be played and the exercises will be performed with the patient along with the CD. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.
Study: NCT05087368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoronaVac (Sinovac Biotech)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoronaVac (Sinovac Biotech)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
Study: NCT05059600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZULRESSO®
Description: Intravenous infusion of ZULRESSO®.
Study: NCT05087368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
Study: NCT05645718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given by (IV) vein
Study: NCT05207644

Intervention type: DRUG
Group type: OTHER
Intervention: 30 mg letrozole followed by 800 mcg misoprostol
Description: 30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
Study: NCT05582395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04495530

Intervention type: OTHER
Intervention: Non-interventional study
Description: semi-structured interviews will take place on one occasion with participants in this study. This is qualitative research, and does not involve any interventions

Intervention type: OTHER
Intervention: Non-interventional study
Description: semi-structured interviews will take place on one occasion with participants in this study. This is qualitative research, and does not involve any interventions
Study: NCT06269757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Exercise Program
Description: The individualized exercise program involves an initial 2D individual running evaluation designed for runners of all ages and abilities, to help improve performance and prevent injury. During the assessment patients receive a one-on-one evaluation with an exercise physiologist that includes:~* Running analysis;~* Training program review;~* Strength and flexibility assessment;~* Review of running video;~* Personalized final report.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Standard of care physical therapy for ITB band syndrome involves exercises designed to target structural weaknesses such as hip abductor weakness. Typical exercises include but are not limited to hip flexor stretches, side lying hip abduction, figure 4 bridges, lateral walks with exercise bands, and side planks.
Study: NCT05645718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given by (IV) vein
Study: NCT05763108

Intervention type: DIAGNOSTIC_TEST
Intervention: genetic test
Description: COL1A1 or COL5A1 genetic test
Study: NCT05645718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given by PO
Study: NCT05763108

Intervention type: DIAGNOSTIC_TEST
Intervention: genetic test
Description: COL1A1 or COL5A1 genetic test

Intervention type: OTHER
Intervention: Beighton joint laxity test
Description: Based on Beighton scale.
Study: NCT05645718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by (IV) vein
Study: NCT05111210

Intervention type: OTHER
Intervention: Blood sample
Description: Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed

Intervention type: OTHER
Intervention: Blood sample
Description: Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed

Intervention type: OTHER
Intervention: Data collection
Description: collection of socio-demographic, clinical and biological data.

Intervention type: OTHER
Intervention: Data collection
Description: collection of socio-demographic, clinical and biological data.

Intervention type: OTHER
Intervention: skin biopsies
Description: skin biopsies of 4 mm in diameter. These samples will not be taken on the face or in an area of skin folds
Study: NCT06273605

Intervention type: OTHER
Group type: OTHER
Intervention: Egg Ladder
Description: 12 month protocol of graded and gradual egg introduction
Study: NCT05579743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote wound monitoring technology
Description: Healthy.io developed a professional-user wound management system that captures wound measurements and analyzes tissue distribution in real time through a smartphone application. Clinical oversight of the healing status of the wound via remote imaging and expert review allows for real time intervention when stagnation or worsening of a wound is detected. Patients with wounds on their legs will receive access to Healthy.io's mobile app and will be able to perform self-scans of their wound which will be automatically sent to the medical professionals, thus allowing them to assess the wound remotely.
Study: NCT06221072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT103
Description: 120 mg by subcutaneous injection every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg by intravenous drip (100mL:4mg) every 4 weeks
Study: NCT05763108

Intervention type: OTHER
Intervention: Beighton joint laxity test
Description: Based on Beighton scale.
Study: NCT05684432

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06791564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVELI
Description: Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVELI
Description: Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVELI
Description: Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.